Abstract
Introduction
Various approaches are used to study specific protein function: gene-targeted knockout animals and knockdown techniques such as anti-sense RNA, RNAi and RNA aptamers [1] [2] [3] . Alternatively, [4] . Gene-targeted knockout mice are a powerful experimental system to examine the role of specific genes or protein isoforms [1] . [3, 5, 6] .
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Nevertheless, the generation of knockout mice is very time consuming and in addition the technique is not applicable in human beings compared to the RNAi, RNA aptamers and intrabody technology which might be applicable in human diseases
Intrabodies can be targeted to different subcellular compartments (cytosol, nucleus, ER, mitochondria) by the use of specific signal peptides [4] . Inside the targeted cell compartment, they can exert their function very effectively and specifically. They have the capacity to block or promote protein-protein or protein-DNA interactions [7] [8] [9] , influence the function of enzymes [9, 10] and inhibit as ER-intrabodies the translocation of cell surface molecules from the ER to the cell surface [4] .
This review is focused on the applications of intrabodies targeted to the ER for inhibiting the transport of cell surface molecules to the plasma membrane. In the paper, the intrabody technology is explained and the in vitro and in vivo applications are reviewed and compared with the gene-silencing technique RNAi
and RNA aptamers. Intracellularly applied aptamers are also called 'intramers' [11] . The RNAi-mediated gene silencing at the transcriptional and post-transcriptional level is an emerging technology platform, which has become the method of choice for targeted knockdown of gene expression in mammalian cells. RNA interference is mediated by small interfering RNAs (siRNAs), which are intracellularly generated from long endogenous double-stranded RNA molecules (dsRNAs) through the cleavage activity of a ribonuclease III-type protein [5] . Alternatively, short hairpin RNA (shRNA) are expressed resulting in knockdown of the target message too [5] .
Furthermore, the potential and limitations of ER intrabodies as therapeutic reagents are discussed.
The advantages of the intrabody technology are (i) the excellent specifity [12] , (ii) very stable expression in mammalian cells (compared to small siRNAs and shRNAs [13] and RNA intramers [14] ) and (iii) the possibility to inactivate and study the function of a specific protein domain (Table 1) [15, 16] . Furthermore, alleles differing by a single nucleotide polymorphism can be targeted by siRNAs [17, 18] , but its major limitation is non-specifity [19, 20] . In addition, transfection of RNAi may result in up-regulation of IFN-stimulated genes [21] depending on the sequence and size of the siRNAs (Table 1) .
The advantages of the RNA aptamer/intramer technology is the high specifity, the possibility to select RNAs with a high affinity to the target by an in vitro selection (Selex: systematic evolution of ligands by exponential enrichment [3] ) and the possibility to (Fig. 1A) . After transport via COPII-coated vesicles, the intrabodytarget protein complex binds via the C-terminal retention sequence (KDEL) inside the cis Golgi network to the human ER receptor hERD2 [22] . Proteins retained inside the ER share a common carboxy-terminal tetrapeptide: KDEL [23] . Initially it was shown that fusion of the sequence SEKDEL from the resident luminal ER protein grp78 to lysozyme led to 100% retention [23] . In addition, fusion of the tetrapeptide KDEL to the secreted protein human proneuropeptide Y (pro-NPY) led to retention, too [24] . For the retention of ER intrabodies, the sequence SEKDEL has been used in almost all studies [4] .
The KDEL signal induces oligomerization of hERD2, recruitment of ArfGAP (involved in COPI coat assembly) and formation of COPI-coated budding complexes [25] . The protein complex is then recycled back via COPI-coated vesicles to the ER (Fig. 1A) . This results in a very efficient down-regulation of the expression of the specific cell surface target molecule on the cell surface. After retrieval to the ER, the proteins dissociate from the receptor and are degraded directly inside the ER [26] or by the cytoplasmic proteosome [27] . Recently, it was shown that the degradation of the intrabody target ß-amyloid precursor protein (APP) was blocked by an inhibitor of the cytosolic proteasome [28] .
Mouse intrabodies will induce a major histocompatibility (MHC) [63] , EGFR [64] , VEGFR-2 [65] , HIV gp120 [66] , CCR5 [67] , CXCR4 [68] , ␣V integrin [69] and prion-like protein PrP [70] [8] . Fig. 1A and B [85] (SEKDEL, [23] [44, 45] and singledomain intrabodies [74] . The bispecific intradiabody simultaneously silences two independent signalling pathways and shows high intracellular stability compared to scFv intrabodies [44, 45] [43] . Furthermore, a new bispecific, tetravalent intradiabody was able to simultaneously knockout both cell surface receptors KDR and Tie-2 [44, 45] . Performed with a human melanoma xenograft mouse model, the intradiabody inhibited tumour growth by 92.2% [45] . [46] . [82] . [47, 48] , the precursor gp160 [49] [47, 48] . [47] . [49] .
Generation of ER-targeted intrabodies
In summary, it could be concluded that ER-targeted anti-VEGFR-2/KDR or anti-Tie-2 intrabodies might be useful for therapeutic application against solid tumours. Another application of anti-oncogenic receptor ER intrabodies was shown with the human folate receptor [46]. The ␣-folate receptor (FR) is selectively overexpressed in 90% of non-mucinous ovarian carcinomas. Folate uptake induces signal transduction associated with dysregulated cell proliferation. Expression of anti-FR intrabodies in ovarian cancer cells led to a dramatic decrease in cell proliferation rate and increased adhesion to various extracellular matrix components accompanied by reversion towards normal phenotype
Last but not least, the ER intrabody technology was used to neutralize proteins involved in tumour development that do not belong to the growth factor receptor family. Intrabodies were generated that block the secretion of proteinases. This was shown for (i) procathepsin L that strongly increases the tumourigenicity and metastatic potential of human melanoma cells [81] and (ii) for the metalloproteinase MMP-2 and MMP-9 which both degrade collagenase IV in the basement membrane and play an important role in tumour invasion and formation of metastasis
ER intrabodies against infectious diseases ER intrabodies against HIV
To prevent the entry of HIV-1 into CD4 + T cells, the
HIV-1 glycoprotein gp120 and the corresponding coreceptors can be targeted by neutralizing antibodies or small molecule antagonists. To inhibit different stages of HIV-1 life cycles, anti-HIV intrabodies have been targeted to structural, regulatory and enzymatic proteins of the virus inside the different compartments of the host cell [47]. The targets of anti-HIV ER intrabodies are the HIV-1 env glycoprotein gp120
Anti-HIV-1 gp120/gp160 intrabodies
An ER intrabody against the envelope protein gp120 led to inhibition of proteolytic processing of the env precursor gp160, decrease of envelope-mediated syncytium formation and reduced infectivity of HIV-1 particles released by intrabody expressing cells
Studies are evaluating the efficiency of the antigp120 intrabody in asymptomatic HIV-1-infected patients, by reinfusing autologous CD4 + T cells that have been transduced ex vivo with a murine leukaemia virus vector encoding this intrabody
Furthermore, an scFv with an ER or trans-Golgi network (TGN) retention signal recognizing the envelope precursor gp160 inhibited HIV-1-induced syncytial formation too
Anti-HIV-1 co-receptor intrabodies
HIV requires a co-receptor, in addition to CD4, for entry into target cells. Macrophage (M)-tropic viruses require the chemokine receptor CCR5 for entry, while T-cell-line (TCL)-tropic viruses use CXCR4 for entry. Intrabodies against CCR5 and CXCR4 led to protection against HIV-1 infection [50-54]. Interestingly, the anti-CCR5 intrabody [50] reacts with CCR5 from non-human primates and the strategy to establish an HIV-1 resistant cell pool in infected patients can be tested in SIV and chimeric simian-human immunodeficiency virus (SHIV) models of human AIDS. Recently the intrabody was transduced into CD34 + foetal liver stem cells and this cells gave rise to CD4 + and CD8 + thymocytes in non-obese diabetic (NOD)/severely combined-immunodeficient (SCID)-human thymus/liver (hu thy/liv) mice [51]. In another approach, the CCR5 surface expression was down-regulated in monocyte-derived macrophages after co-infection of Tag-deleted SV40-derived vector encoding an anti-CCR5 scFv fragment and a hammerhead CCR5-specific ribozyme. The combination of both transgenes prevented the cells from HIV-1 infection after challenge with high dosis of HIV-1 [52]. In addition, recently a new anti-CXCR4 intrabody was described that inhibits infectious entry of HIV-1 in primary isolated human brain microvascular endothelial cells and post-mitotic differentiated human neurons [54]. This example opens the possibility to develop strategies to apply such intrabodies against HIV-1-related neurodegenerative disorders and neuroinvasion. In summary, the antienvelope intrabodies might be used to generate cells that produce virions that are markedly less infectious, whereas the anti-CCR5/CXCR4 intrabodies might be used in clinical gene therapy strategies to generate a cell pool in infected patients that is protected from HIV-1 infection.
ER intrabodies to other viruses
A recombinant ER-targeted Fab fragment against the Hepatitis C virus core protein was described, and co-localization and intracellular binding was shown [83] . Two [85] . [88] whereas ER intrabodies inhibited the cleavage or translocation of cell surface proteins from the ER to the cell surface that play an important role in the biogenesis of Alzheimer's and Prion diseases: ␤-APP [28] and PrP c [61, 62] .
Abrogation of MHC I molecules
Presentation of intracellularly synthesized peptides in a complex with MHC class I molecules on the cell surface of donor cells is the central reason for rejection of allogeneic cell and tissue transplants. The generation of transplantable in vitro generated
ER intrabodies targeting integrins
ER intrabodies targeting proteins involved in Alzheimer's and Prion disease
Misfolded and accumulated intracellular proteins characterize a wide range of neurodegenerative disorders. Proteins involved in the Huntington's and Parkinson's diseases were successfully targeted by cytoplasmic and nucleus-targeted intrabodies
Endoproteolysis of the ␤-APP by ␤-and ␥-secretases generates the toxic amyloid ␤-peptide (A␤), which accumulates in the brain of Alzheimer's disease (AD) patients. Generation of the toxic amyloid ␤-peptide was prevented by ER expression of an intrabody recognizing an epitope adjacent to the ␤-secretase cleavage site of the human ␤-APP [28] . In the case of Prion disease, SEKDEL-tagged antiprion intrabodies were able to prevent abnormal scrapie isoform accumulation and inhibit prion infectivity in mice [61, 62] . These ER intrabodies are useful tools to study in more detail the cellular traffic and degradation of this important protein.
Intrabody gene delivery
The transfer of intrabody genes into living cells can be performed with viral or non-viral transfer systems. [34-37, 42-45, 56, 57, 60] , murine leukaemia virus [32, 33, 39, 40, 47, 48, 50, 53] , HIV-1-based lentivirus [30, 31, 51, 54] , SV40-derived vector [52, 53, 89] and adeno-associated virus (AAV) [47] [90] . Nevertheless, for in vitro transduction of ER intrabodies into cell lines [34, 35, 56, 60] and primary cells [42, 56, 57] and in mouse tumour models, recombinant adenovirus has been successfully employed [36, 43, 45, 60] . [91] [95] . In contrast to adenoviral vectors, envelope alterations of retroviral vectors including lentivirus affect in most cases viron assembly and lead to low fusion or defective fusion activity [96, 99] . With regard to the retargeting of lentivirus, two new reports performed with Sindbis pseudotyped lentiviral vectors were described displaying an anti-CCR5 scFv fragment [100] and an anti-P-glycoprotein antibody [101] . The modified lentivirus expressing the anti-P-glycoprotein antibody on the viron surface were successfully retargeted to P-glycoprotein on metastatic melanoma through intravenous injection of mice [101] . These two studies can be considered as a powerful approach for specific viral gene delivery mediated by Sindbis envelope that displays singlechain antibody fragments recognizing specific cellular surface proteins. 
Viral vectors
ER intrabody gene transfer was performed with adenovirus
The advantage of lentiviral vectors is their capacity of integrating into non-deviding cells that constitute the targets of HIV-1 infection such as resting T cells, dendritic cells and macrophages and have been widely used in preclinical studies
Non-viral transfer systems
